

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN LABORATORIES LTD.
Petitioner

v.

JANSSEN PHARMACEUTICA NV
Patent Owner

Case IPR2020-00440
Patent 9,439,906

PATENT OWNER'S PRELIMINARY RESPONSE

TABLE OF CONTENTS

	<u>Page</u>
I. INTRODUCTION	1
II. THE BOARD SHOULD EXERCISE ITS DISCRETION UNDER 35 U.S.C. § 314(a) TO DENY MYLAN’S PETITION	6
A. The Timing of Mylan’s Petition Supports Discretionary Denial.....	7
B. Co-Pending Litigation Involving the 906 Patent	11
1. <i>Apple</i> Factors 1 and 2: The Absence of a Stay and Proximity of Trial Date	12
2. <i>Apple</i> Factor 3: The Court’s and Parties’ Investment in the Parallel Proceedings.....	13
3. <i>Apple</i> Factor 4: Overlapping Issues	14
4. <i>Apple</i> Factor 5: Same Parties in Parallel Proceeding.....	16
5. <i>Apple</i> Factor 6: Other Circumstances Including the Merits	16
6. <i>Apple</i> : Other Considerations	17
III. GROUNDS 1 AND 2 OF MYLAN’S PETITION RELY ON REFERENCES THAT ARE NOT PRIOR ART	20
IV. MYLAN’S PETITION AND ACCOMPANYING EXPERT TESTIMONY ARE CONCLUSORY, HINDSIGHT-DRIVEN, AND UNSUPPORTED OR CONTRADICTED BY THE RECORD	25
A. Failure to Address Obviousness of the Unique Combination of Elements	28
B. No Motivation to Administer Two Loading Doses in the Deltoid Muscle Only	30
1. Grounds 1 and 2	30
2. Grounds 3 and 4	34
C. No Motivation to Use a 150 mg-eq. First Loading Dose.....	38
1. Citrome.....	39
2. PI-74 and PI-75	43
3. Alleged Overlapping Ranges	46
D. No Motivation to Use a Lower 100 mg-eq. Second Loading Dose Following the 150 mg-eq. First Loading Dose	48

TABLE OF CONTENTS
(continued)

	<u>Page</u>
E. No Motivation to Arrive at Claimed Lower Dose Amounts for Renally Impaired Patients	53
F. No Reasonable Expectation of Success	55
V. MYLAN FAILS TO PROVIDE EVIDENTIARY FOUNDATIONS FOR ITS OBVIOUSNESS GROUNDS	61
A. Failure to Address Site of Administration of Maintenance Doses	61
B. Failure to Address Maintenance Dose Monthly Dosing Windows	63
C. Failure to Address Motivation to Combine PI-74 and PI-75	63
VI. CONCLUSION.....	65

TABLE OF AUTHORITIES

	Page(s)
Cases	
<i>Advanced Bionics, LLC v. MED-EL Elektromedizinische Geräte GmbH,</i> IPR2019-01469, Paper 6 (Feb. 13, 2020).....	17, 18, 19
<i>Alcon Research Ltd. v. Barr Labs., Inc.,</i> 837 F. Supp. 2d 364 (D. Del. 2011), <i>aff'd in part, rev'd in part on other grounds</i> , 745 F.3d 1180 (Fed. Cir. 2014).....	21, 22
<i>Alliance Indus. Corp. v. Gebo Cermex USA, Inc.,</i> IPR2019-01647, Paper 9 (PTAB Mar. 24, 2020).....	26
<i>Apple Inc. v. Fintiv, Inc.,</i> IPR2020-00019, Paper 11 (PTAB Mar. 20, 2020).....	<i>passim</i>
<i>Apple Inc. v. Fintiv, Inc.,</i> IPR2020-00019, Paper 15 (PTAB May 13, 2020)	11
<i>Arris Solutions, Inc. v. Realtime Adaptive Streaming LLC,</i> IPR2019-01586, Paper 7 (PTAB Mar. 16, 2020).....	40
<i>Ex Parte Bayer,</i> No. 2012-006699, 2013 WL 3972367 (PTAB July 31, 2013).....	21, 22
<i>Becton, Dickinson & Co. v. B. Braun Melsungen AG,</i> IPR2017-01586, Paper 8 (PTAB Dec. 15, 2017)	17
<i>Belden, Inc. v. Berk-Tek LLC,</i> 805 F.3d 1064 (Fed. Cir. 2015)	40
<i>Dr. Reddy's Laboratories, Ltd. v. Monosol RX, LLC,</i> IPR2016-01111, Paper 14 (PTAB Dec. 5, 2016)	60
<i>Dynamic Drinkware, LLC v. Nat'l Graphics, Inc.,</i> 800 F.3d 1375 (Fed. Cir. 2015)	20

<i>E.I. duPont de Nemours & Co. v. Synvina C.V.</i> , 904 F.3d 996 (Fed. Cir. 2018)	46, 48
<i>Eisai Co. v. Dr. Reddy's Labs., Ltd.</i> , 533 F.3d 1353 (Fed. Cir. 2008)	36
<i>Eli Lilly & Co. v. Sicor Pharm., Inc.</i> , 705 F. Supp. 2d 971 (S.D. Ind. 2010).....	21
<i>Enovate Medical, LLC, v. Intermetro Indus. Corp.</i> , IPR2015-00300, Paper 12 (PTAB May 20, 2015)	64
<i>Ericsson, Inc. v. Intellectual Ventures I LLC</i> , 890 F.3d 1336 (Fed. Cir. 2018)	34, 37, 45, 51
<i>Gen. Elec. Co. v. United Tech. Corp.</i> , IPR2017-00428, Paper No. 38 (PTAB June 22, 2018)	29
<i>Gillette Co. v. S.C. Johnson & Son, Inc.</i> , 919 F.2d 720 (Fed. Cir. 1990)	29
<i>Harmonic, Inc. v. Avid Tech., Inc.</i> , 815 F.3d 1356 (Fed. Cir. 2016)	25
<i>Hulu, LLC v. Sound View Innovations, LLC</i> , IPR2018-01039, Paper 29 (PTAB Dec. 20, 2019)	35
<i>Hybritech, Inc. v. Monoclonal Antibodies, Inc.</i> , 802 F.2d 1367 (Fed. Cir. 1986)	28, 29
<i>InfoBionic, Inc. v. Braemar Mfg., LLC</i> , IPR2015-01704, Paper 11 (PTAB Feb. 16, 2016).....	26, 38, 40, 50
<i>Institut Pasteur v. Focarino</i> , 738 F.3d 1337 (Fed. Cir. 2013)	61
<i>Intelligent Bio-Systems v. Illumina Cambridge, Ltd.</i> , 821 F.3d 1359 (Fed. Cir. 2016)	55
<i>Ioxus, Inc. v. CAP-XX, Ltd.</i> , IPR2019-01179, Paper 77 (PTAB Dec. 4, 2019)	63

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.